Kiora Pharmaceuticals Inc. (KPRX) Stock Price, Quote & News

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 224 9600

Website: www.kiorapharma.com

Address:

332 Encinitas Boulevard, Suite 102, Encinitas, United States

SimSimBola Nov. 10 at 6:50 PM

$KPRX data readout about 1 year away. thats too long to get money tied up, imo

0 · Reply

OpenOutcrier Nov. 7 at 1:25 PM

$KPRX (+6.9% pre) Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases https://ooc.bz/l/83640

0 · Reply

Jake140 Nov. 7 at 12:33 PM

$KPRX

0 · Reply

newsfile_corp Nov. 7 at 11:02 AM

https://nfne.ws/273499 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResults #Results #NASD

0 · Reply

TradeHuntFish Oct. 31 at 3:09 PM

PW’s current price undervalues what could be a strategic reset. With cash reserves intact and hundreds of months of potential runway, the downside seems limited. The upside? A clean breakout if technicals align and narrative catches up. $MBOT $SNMP $TRKA $KPRX

0 · Reply

KioraIR Oct. 30 at 2:18 PM

$KPRX We're honored to join Global Genes' RARE-X Vision Consortium. Working together, advocacy groups, drug developers and researchers will be able to accelerate development of new treatments for rare eye diseases. Read More > https://ir.kiorapharma.com/news-events/news-releases/detail/240/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders

0 · Reply

ChaseDeluca Oct. 29 at 12:39 AM

SSKN is undervalued, under‑noticed, and potentially ready to re rate. A new peer reviewed journal study. Growing indications for its laser platform. Minimal float. All the pieces for an asymmetric move. If volume spikes and shorts scramble, the upside could surprise. $COSM $AVTX $DSS $KPRX

1 · Reply

Jake140 Oct. 24 at 10:11 AM

$KPRX

0 · Reply

JoshThe3rd Oct. 23 at 6:04 PM

$KPRX Earnings should be around November 8th. Hoping enrollment for KIO-104 is complete. Priced so low because the market doesn't like trial execution. But as you've seen it just takes a spark to ignite this.

1 · Reply

romarcin23 Oct. 22 at 5:45 PM

$KPRX @kprx. Do you think this dramatic fall is due to insider info? or over all market trend?

1 · Reply

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Oct 30, 2025, 9:00 AM EDT - 16 days ago

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Oct 15, 2025, 7:00 AM EDT - 4 weeks ago

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Aug 8, 2025, 7:00 AM EDT - 3 months ago

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

Jul 22, 2025, 8:55 AM EDT - 4 months ago

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

May 9, 2025, 7:00 AM EDT - 6 months ago

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

Apr 4, 2025, 7:00 AM EDT - 8 months ago

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 7:00 AM EDT - 8 months ago

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Mar 12, 2025, 7:00 AM EDT - 8 months ago

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Feb 13, 2025, 7:00 AM EST - 9 months ago

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Feb 11, 2025, 6:45 AM EST - 9 months ago

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Nov 8, 2024, 7:00 AM EST - 1 year ago

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Oct 29, 2024, 6:45 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Sep 25, 2024, 9:55 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 9, 2024, 4:55 PM EDT - 1 year ago

Bonds still bouncing along

CPLS EYEG HYFI JPST TLT USHY YEAR

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Jul 30, 2024, 6:45 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

DARE

Jun 25, 2024, 6:45 AM EDT - 1 year ago

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

May 10, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

May 8, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

May 6, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Mar 28, 2024, 6:45 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Mar 8, 2024, 7:00 AM EST - 1 year ago

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Jan 31, 2024, 6:40 PM EST - 1 year ago

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Jan 31, 2024, 5:15 PM EST - 1 year ago

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

Dec 13, 2023, 7:30 AM EST - 2 years ago

AllianceBernstein Launches Five New Active ETFs

AB BUFC CPLS EYEG TAFL TAFM

Nov 9, 2023, 7:18 AM EST - 2 years ago

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Nov 4, 2023, 12:15 PM EDT - 2 years ago

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Sep 14, 2023, 7:01 AM EDT - 2 years ago

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Sep 1, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Aug 29, 2023, 1:43 PM EDT - 2 years ago

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Aug 23, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Aug 22, 2023, 1:06 PM EDT - 2 years ago

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Jul 5, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease

Jun 15, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

SimSimBola Nov. 10 at 6:50 PM

$KPRX data readout about 1 year away. thats too long to get money tied up, imo

0 · Reply

OpenOutcrier Nov. 7 at 1:25 PM

$KPRX (+6.9% pre) Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases https://ooc.bz/l/83640

0 · Reply

Jake140 Nov. 7 at 12:33 PM

$KPRX

0 · Reply

newsfile_corp Nov. 7 at 11:02 AM

https://nfne.ws/273499 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResults #Results #NASD

0 · Reply

TradeHuntFish Oct. 31 at 3:09 PM

0 · Reply

KioraIR Oct. 30 at 2:18 PM

0 · Reply

ChaseDeluca Oct. 29 at 12:39 AM

1 · Reply

Jake140 Oct. 24 at 10:11 AM

$KPRX

0 · Reply

JoshThe3rd Oct. 23 at 6:04 PM

1 · Reply

romarcin23 Oct. 22 at 5:45 PM

$KPRX @kprx. Do you think this dramatic fall is due to insider info? or over all market trend?

1 · Reply

ChaseDeluca Oct. 22 at 8:51 AM

GIPR has optionality baked in. Real estate gives downside protection. A story shift (tokenization of assets, digital‑asset holdings, lease re‑ratings) gives upside. At current levels, the range up to $10+, even $13+, starts feeling very plausible when the market recognizes it. $VCIG $AVTX $YOSH $KPRX

0 · Reply

frontiere Oct. 20 at 1:08 PM

$KPRX Kiora ref=$2.71 — slowly building Long size — catalysts far but chart Lindy and at support , neg EV (MCap<cash till 2027 at least) w low float. From 2025-09-15 S-3 mixed shelf https://www.sec.gov/Archives/edgar/data/1372514/000137251425000072/s-3xseptember2025.htm

0 · Reply

Ling23 Oct. 20 at 9:18 AM

$KPRX Does anyone know Stephen From?? I believe he was with this company?

0 · Reply

ChaseDeluca Oct. 15 at 5:22 PM

GIPR is trading like real estate, but there’s potential for so much more. Assets under the hood + possibility of a crypto treasury pivot = upside few are pricing in. If they lean into digital assets, this could re-rate dramatically. $SNMP $MODD $CEI $KPRX $MBRX

0 · Reply

Jake140 Oct. 15 at 12:15 PM

$KPRX

0 · Reply

newsfile_corp Oct. 15 at 11:01 AM

https://nfne.ws/270410 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

0 · Reply

Jake140 Oct. 13 at 11:13 AM

$KPRX Patience is key with this one...holding!

0 · Reply

ThirstyFishy Oct. 10 at 12:41 AM

$KPRX This company is so small that it can easily triple it's market cap in a single day. I expect it to happen, but I don't know when, so I'm just going to wait until it happens because it will happen

1 · Reply

JamesBenjaMin Oct. 7 at 1:07 AM

This is a rare setup PRHI trading at its bottom, daily golden cross coming, and the short data backing the squeeze narrative. The upside range is wide, and with few shares to borrow, every bit of buying pressure can fuel big moves. $PRFX $SNMP $KPRX $MGAM $OPGN

0 · Reply

Jake140 Oct. 5 at 2:12 PM

$KPRX

0 · Reply

rangeyuri Oct. 5 at 9:25 AM

$KPRX Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.

0 · Reply

TradeHuntFish Oct. 3 at 1:52 AM

GIPR could morph from underpriced REIT to digital treasury giant. Imagine it holding Bitcoin, Ethereum, or stablecoins on its balance sheet while still collecting real estate income. That hybrid model could lead to massive revaluation especially in a market chasing yield + digital assets. $VEEE $AVTX $KPRX $WKEY $GNS

0 · Reply

Market Cap	8.07M
Revenue (ttm)	16.02M
Net Income (ttm)	3.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	22.41%
Debt to Equity Ratio	0.00

Volume	48,900
Avg Vol	42,286
Day's Range	N/A - N/A
Shares Out	3.68M
Stochastic %K	0%
Beta	-0.70
Analysts	Sell
Price Target	$12.00